Announcements Trials
Browse Landscape

Phase

Phase 3 23Phase 2 22Phase 4 6Phase 2/3 4Phase NA 2

Status

Recruiting 3Active not recruiting 1

Sponsor Class

OTHER 3FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4Lymphoid 2Sarcoma 1

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 1Castration-resistant Prostate Cancer Patients with Oligometastases 1

Interventions

Gemcitabine 9Docetaxel 8Androgen Antagonists 7acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 6Magnetic Resonance Spectroscopy 6gallium 68 PSMA-11 5Prednisone 5Leuprolide 5Goserelin 5Cisplatin 5enzalutamide 4bicalutamide 4Triptorelin Pamoate 4Radiosurgery 4Carboplatin 42-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 4luprolide acetate gel depot 3Flutamide 3Celecoxib 3valrubicin 2pembrolizumab 2nilutamide 2cabazitaxel 2abiraterone 2Zoledronic Acid 2Vinblastine 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Radiotherapy 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2/3 × Triptorelin Pamoate × Genitourinary × Clear all
NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT06282588 2026-03-19

THUNDER

Cancer Research Antwerp

Phase 2/3 Recruiting
493 enrolled
Genitourinary

Prostatic Neoplasms

NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

NCT04242017 2023-12-13

LOBSTER

Universitaire Ziekenhuizen KU Leuven

Phase 2/3 Recruiting
394 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡